TSBX NASDAQ
Turnstone Biologics Corp.
1W: +1.1%
1M: -3.6%
3M: +4.4%
1Y: -83.6%
$0.35
Last traded 2025-08-11 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.2M
52W Range0.29-2.2614
Volume283,774
Avg Volume404,925
Beta1.37
Dividend—
Analyst Ratings
Company Info
CEOSammy J. Farah
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-21
Websiteturnstonebio.com
9310 Athena Circle
LA Jolla, CA 92037
US
LA Jolla, CA 92037
US
347-897-5988
About Turnstone Biologics Corp.
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | U-Tender | 3,099,265 | $0.34 | 2025-08-08 |
| Versant Ventures V, | U-Tender | 274,990 | $0.34 | 2025-08-08 |
| Jerel Davis | U-Tender | 82,006 | $0.34 | 2025-08-08 |
| Gupta Rishi | U-Tender | 3,099,265 | $0.34 | 2025-08-08 |
| Rajangam Kanya | A-Award | 12,770 | $2.69 | 2024-06-03 |